

Appl. No. 10/601,607
Atty. Dkt. No. 054707-1225
Response To Final Office Action Dated March 7, 2005


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-71 (Canceled).

Claim 72. (Previously presented) A compound of formula (I):



where

















n is 1;

R₁ is selected from the group consisting of hydrogen, C₁-C₉ straight or branched chain alkyl, C₃-C₉ straight or branched chain alkenyl, aryl, heteroaryl, carbocycle, and heterocycle;


D is selected from the group consisting of a bond, C₁-C₁₀ straight or branched chain alkylene, C₂-C₁₀ alkenylene, and C₂-C₁₀ alkynylene;

Appl. No. 10/601,607
Atty. Dkt. No. 054707-1225
Response To Final Office Action Dated March 7, 2005

R₂ is selected from the group consisting of:



and




Appl. No. 10/601,607
Atty. Dkt. No. 054707-1225
Response To Final Office Action Dated March 7, 2005

wherein for R_1 said alkyl, alkenyl, alkylene, alkenylene, alkynylene, aryl, heteroaryl, carbocycle, or heterocycle is optionally substituted with one or more substituents selected from R_3 , where

R_3 is selected from the group consisting of hydrogen, hydroxy, halo, haloalkyl, thiocarbonyl, alkoxy, alkenoxy, alkylaryloxy, aryloxy, arylalkyloxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, alkylthio, sulfonyl, C_1 - C_6 straight or branched chain alkyl, C_2 - C_6 straight or branched chain alkenyl or alkynyl, aryl, heteroaryl, carbocycle, heterocycle, and CO_2R_4 where R_4 is selected from the group consisting of hydrogen, C_1 - C_9 straight or branched chain alkyl, and C_2 - C_9 straight or branched chain alkenyl;
or a pharmaceutically acceptable salt or solvate thereof.


Claim 73. (Previously presented) The compound of claim 72, wherein the compound is non-immunosuppressive.

Claim 74. (Previously presented) A compound according to claim 72, wherein R_2 is selected from the group consisting of



Appl. No. 10/601,607
 Atty. Dkt. No. 054707-1225
 Response To Final Office Action Dated March 7, 2005






Claim 75. (Currently amended) A compound selected from the group consisting of (2S)-1-(phenylmethyl)sulfonyl-2-hydroxymethyl pyrrolidine, (2S)-1-(phenylmethyl)sulfonyl-2-pyrrolidinetetrazole, and compounds 1-9, 21-25, 30-38, 42-57, 59, 66-97, A, B, C, D, and E the compounds of formula (I):








wherein n, D, R₂ and R₁ are:

<u>n</u>	<u>D</u>	<u>R₂</u>	<u>R₁</u>
<u>1</u>	<u>bond</u>	<u>Tetrazole</u>	<u>Benzyl,</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>






Appl. No. 10/601,607
Atty. Dkt. No. 054707-1225
Response To Final Office Action Dated March 7, 2005

<u>n</u>	<u>D</u>	<u>R₂</u>	<u>R₁</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>


Appl. No. 10/601,607
Atty. Dkt. No. 054707-1225
Response To Final Office Action Dated March 7, 2005

<u>n</u>	<u>D</u>	<u>R₂</u>	<u>R₁</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>


Appl. No. 10/601,607
Atty. Dkt. No. 054707-1225
Response To Final Office Action Dated March 7, 2005

<u>n</u>	<u>D</u>	<u>R₂</u>	<u>R₁</u>
1	<u>bond</u>		<u>Benzyl.</u>
1	<u>bond</u>		<u>Benzyl.</u>
1	<u>bond</u>		<u>Benzyl.</u>
1	<u>bond</u>		<u>Benzyl.</u>
1	<u>bond</u>		<u>Benzyl, and</u>

Appl. No. 10/601,607
 Atty. Dkt. No. 054707-1225
 Response To Final Office Action Dated March 7, 2005



Claim 76. (Previously presented) A pharmaceutical composition, comprising:
 a) an effective amount of a compound having formula (I):






where

n is 1;


R₁ is selected from the group consisting of hydrogen, C₁-C₉ straight or branched chain alkyl, C₂-C₉ straight or branched chain alkenyl, aryl, heteroaryl, carbocycle, and heterocycle;

D is selected from the group consisting of a bond, C₁-C₁₀ straight or branched chain alkylene, C₂-C₁₀ alkenylene, and C₂-C₁₀ alkynylene;

R₂ is selected from the group consisting of:



Appl. No. 10/601,607
 Atty. Dkt. No. 054707-1225
 Response To Final Office Action Dated March 7, 2005



wherein for R_1 said alkyl, alkenyl, alkylene, alkenylene, alkynylene, aryl, heteroaryl, carbocycle, or heterocycle is optionally substituted with one or more substituents selected from R_3 , where

R_3 is selected from the group consisting of hydrogen, hydroxy, halo, haloalkyl, thiocarbonyl, alkoxy, alkenoxy, alkylaryloxy, aryloxy, arylalkyloxy, cyano, nitro,

Appl. No. 10/601,607

Atty. Dkt. No. 054707-1225


Response To Final Office Action Dated March 7, 2005

imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, alkylthio, sulfonyl, C₁-C₆ straight or branched chain alkyl, C₂-C₆ straight or branched chain alkenyl or alkynyl, aryl, heteroaryl, carbocycle, heterocycle, and CO₂R₄ where R₄ is selected from the group consisting of hydrogen, C₁-C₉ straight or branched chain alkyl, and C₂-C₉ straight or branched chain alkenyl;

or a pharmaceutically acceptable salt or solvate thereof; and

b) a pharmaceutically acceptable carrier.






Claim 77. (Currently amended) The pharmaceutical composition of claim 76, wherein the compound is selected from the group consisting of ~~compounds 4 and 76-94~~ compounds of formula (I):








wherein n, D, R₂ and R₁ are:

<u>n</u>	<u>D</u>	<u>R₂</u>	<u>R₁</u>
<u>1</u>	<u>bond</u>	<u>Tetrazole</u>	<u>Benzyl,</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>






Appl. No. 10/601,607
Atty. Dkt. No. 054707-1225
Response To Final Office Action Dated March 7, 2005

<u>n</u>	<u>D</u>	<u>R₂</u>	<u>R₁</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>


Appl. No. 10/601,607
Atty. Dkt. No. 054707-1225
Response To Final Office Action Dated March 7, 2005

<u>n</u>	<u>D</u>	<u>R₂</u>	<u>R₁</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>

Appl. No. 10/601,607
Atty. Dkt. No. 054707-1225
Response To Final Office Action Dated March 7, 2005

<u>n</u>	<u>D</u>	<u>R₂</u>	<u>R₁</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>
<u>1</u>	<u>bond</u>		<u>Benzyl,</u>

Appl. No. 10/601,607
 Atty. Dkt. No. 054707-1225
 Response To Final Office Action Dated March 7, 2005




Claim 78. (Withdrawn) The pharmaceutical composition of claim 76, further comprising a neurotrophic factor different from those of formula (I).

Claim 79. (Withdrawn—Currently amended) The pharmaceutical composition of claim 78, wherein said neurotrophic factor different from those of formula (I) is selected from the group consisting of ~~neurotrophic growth factor~~ nerve growth factor, ~~brain derived growth factor~~ brain-derived neurotrophic factor, ~~glial-derived growth factor~~ glial cell line-derived neurotrophic factor, ciliary neurotrophic factor, insulin growth factor and active truncated derivatives thereof, acidic fibroblast growth factor, basic fibroblast growth factor, platelet-derived growth factor, neurotrophin-3, and ~~neurotrophin-4/5~~ neurotrophin-4 and neurotrophin-5.

Appl. No. 10/601,607
Atty. Dkt. No. 054707-1225
Response To Final Office Action Dated March 7, 2005

Claim 80. (Previously presented) A composition according to claim 76, wherein R₂ is selected from the group consisting of



Claims 81-85 (Canceled).